Erasca to Present Expanded Clinical Data for ERAS-0015 at EORTC-NCI-AACR Symposium
Event summary
- Erasca will present updated monotherapy clinical data for ERAS-0015 in an oral presentation at the 38th EORTC-NCI-AACR Symposium on November 20, 2026.
- Nonclinical combination data for ERAS-0015 and ERAS-4001 will be shared in a poster presentation at the same event.
- ERAS-0015 is a pan-RAS molecular glue in development for RAS-mutant solid tumors, while ERAS-4001 is a pan-KRAS inhibitor for KRAS-mutant solid tumors.
- Erasca aims to advance three potentially registration-enabling trials for ERAS-0015 in pancreatic and lung cancers.
The big picture
Erasca's presentations at the EORTC-NCI-AACR Symposium highlight its focus on precision oncology, particularly targeting the RAS/MAPK pathway. The company's approach aims to comprehensively shut down this pathway, which is a critical driver in many cancers. The strategic significance lies in Erasca's potential to differentiate itself in the competitive oncology space through novel combination therapies and its singular focus on RAS/MAPK-driven cancers.
What we're watching
- Clinical Efficacy
- How the expanded monotherapy data for ERAS-0015 will impact its potential as a best-in-class treatment for RAS-mutant cancers.
- Combination Therapy
- Whether the synergy demonstrated between ERAS-0015 and ERAS-4001 in KRAS G12X-driven models will translate into clinical benefits.
- Regulatory Pathway
- The pace at which Erasca can advance toward registration-enabling trials for ERAS-0015 in pancreatic and lung cancers.
Related topics